Kelman-Lazarov Inc’s Biogen BIIB Stock Holding History

Kelman-Lazarov Inc’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-200	Closed	-$56.7K	–	117
2016 Q4	$56.7K	Hold	200	–	–	0.03%	155
2016 Q3	$62.3K	Hold	200	–	–	0.04%	168
2016 Q2	$49K	Hold	200	–	–	0.03%	172
2016 Q1	$52K	Buy	+200	New	+$52.8K	0.03%	181

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kelman-Lazarov Inc's BIIB Position: Q1 2017 in Review

Kelman-Lazarov Inc sold out of Biogen (BIIB) in Q1 2017, closing a stake of 200 shares — an estimated $56.7K sold.

Kelman-Lazarov Inc first reported a position in BIIB in Q1 2016 and held it in 4 quarters. The position peaked at $62.3K in Q3 2016. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

Kelman-Lazarov Inc reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
Kelman-Lazarov Inc sold 200 Biogen shares in Q1 2017, an estimated $56.7K.
Kelman-Lazarov Inc first reported a position in Biogen in Q1 2016 and held it in 4 quarters.
Kelman-Lazarov Inc's Biogen position peaked at $62.3K in Q3 2016.
1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on Kelman-Lazarov Inc's 13F filing for Q1 2017, filed 25 Apr 2017.